• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Willard Stephen H

    4/3/26 5:00:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Willard Stephen H

    (Last)(First)(Middle)
    1951 NW 7TH AVENUE SUITE 520

    (Street)
    MIAMI FLORIDA 33136

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Longeveron Inc. [ LGVN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/01/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock04/01/2026F4,740(1)D$1.12289,727(2)D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award.
    2. Includes RSUs subject to future vesting.
    Remarks:
    /s/ Paul T. Lehr, Attorney-in-fact04/03/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Longeveron Inc.

    DEFA14A - Longeveron Inc. (0001721484) (Filer)

    5/20/26 4:11:44 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Longeveron Inc.

    DEF 14A - Longeveron Inc. (0001721484) (Filer)

    5/20/26 4:10:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Longeveron Inc.

    SCHEDULE 13G - Longeveron Inc. (0001721484) (Subject)

    5/15/26 11:43:27 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CTO & SVP of CMC Blass Devin was granted 250,000 shares, increasing direct ownership by 131% to 441,543 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    5/5/26 6:00:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Willard Stephen H was granted 500,000 shares, increasing direct ownership by 173% to 789,727 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    5/5/26 6:00:15 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agafonova Nataliya was granted 250,000 shares, increasing direct ownership by 123% to 453,419 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    5/5/26 6:00:12 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

    MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B®). Longeveron is progressing through a significant inflection point in the Company's history. After taking on the CEO role in February, we embarked on two immediate critical task

    5/20/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

    On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi

    5/13/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

    Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new safety concerns, and recommended continuation of the study as designed through completionThis review represents the final planned independent safety assessment prior to completion of the trialELPIS II top-line trial results anticipated in August 2026 MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announce

    5/11/26 9:10:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/12/24 7:00:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Longeveron with a new price target

    EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

    1/5/22 10:22:40 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

    MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B®). Longeveron is progressing through a significant inflection point in the Company's history. After taking on the CEO role in February, we embarked on two immediate critical task

    5/20/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

    On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi

    5/13/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

    MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13759888  Call me™ Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" se

    5/5/26 4:15:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    7/26/24 4:18:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care